Haemonetics (HAE) To Report Earnings Tomorrow: Here Is What To Expect
Blood products company Haemonetics (NYSE:HAE). will be reporting results tomorrow before market open. Here's what you need to know.
Haemonetics missed analysts' revenue expectations by 1.3% last quarter, reporting revenues of $348.5 million, up 3.7% year on year. It was a slower quarter for the company, with organic revenue in line with analysts' estimates.
Is Haemonetics a buy or sell going into earnings? Read our full analysis here, it's free.
This quarter, analysts are expecting Haemonetics's revenue to decline 4.7% year on year to $327.3 million, a reversal from the 12.8% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.22 per share.
Haemonetics Total Revenue
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Haemonetics has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 2.7% on average.
Looking at Haemonetics's peers in the medical devices & supplies - specialty segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Inspire Medical Systems delivered year-on-year revenue growth of 22.7%, beating analysts' expectations by 3.1%, and Integer Holdings reported revenues up 7.3%, topping estimates by 2%. Inspire Medical Systems traded up 1.8% following the results while Integer Holdings was also up 2.6%.
Read our full analysis of Inspire Medical Systems's results here and Integer Holdings's results here.
There has been positive sentiment among investors in the medical devices & supplies - specialty segment, with share prices up 5.9% on average over the last month. Haemonetics is up 13.5% during the same time and is heading into earnings with an average analyst price target of $96.30 (compared to the current share price of $63.58).
When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we've found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Endeavour Silver Announces 2025 Annual General Meeting Voting Results and Retirement of Ricardo Campoy
VANCOUVER, British Columbia, June 03, 2025 (GLOBE NEWSWIRE) -- Endeavour Silver Corp. ('Endeavour' or the 'Company') (NYSE: EXK; TSX: EDR) is pleased to announce that shareholders voted in favour of all items of business at the Company's 2025 Annual General Meeting ('AGM') held on June 3, 2025 in Vancouver. A total of 137,600,042 votes were cast or represented by proxy at the AGM, representing 50.23% of the outstanding common shares as of the record date. The following is a tabulation of the votes submitted by proxy: DIRECTORS NUMBER OF SHARES PERCENTAGE OF VOTES CAST FOR WITHHELD/ ABSTAIN FOR WITHHELD Rex J. McLennan 78,925,775 16,641,936 82.59% 17.41% Margaret M. Beck 94,445,855 1,121,856 98.83% 1.17% Daniel Dickson 94,821,211 746,500 99.22% 0.78% Amy Jacobsen 94,670,510 897,202 99.06% 0.94% Angela Johnson 93,733,044 1,834,668 98.08% 1.92% Kenneth Pickering 80,323,860 15,243,851 84.05% 15.95% Mario D. Szotlender 93,983,060 1,584,651 98.34% 1.66% All director nominees were re‑elected. Shareholders voted 98.50% in favour of setting the number of directors at seven. In addition, shareholders also voted 86.58% in favour of re‑appointing KPMG LLP as auditor of the Company and authorized the Board to fix the auditor's remuneration for the ensuing year. Retirement of Ricardo Campoy The Company would like to extend its deepest gratitude to Ricardo Campoy for his 14 years of commitment to the Board. 'On behalf of the Board, I would like to express our sincere appreciation to Ricardo for his steadfast leadership and many contributions over the years,' said Rex McLennan, Chairman of the Board. 'His experience and guidance have been instrumental to the Company's progress, and we wish him the best as he moves into this next chapter of retirement.' About Endeavour Silver Endeavour is a mid-tier precious metals company with a strong commitment to sustainable and responsible mining practices. With operations in Mexico and Peru, and the development of the new cornerstone mine in Jalisco state, the company aims to contribute positively to the mining industry and the communities in which it operates. In addition, Endeavour has a portfolio of exploration projects in Mexico, Chile and the United States to facilitate its goal to become a premier senior silver producer. Contact Information Allison PettitDirector, Investor RelationsEmail: apettit@ Website:
Business Wire
an hour ago
- Business Wire
IonQ Completes Acquisition of Lightsynq, Accelerating Quantum Computing and Networking Roadmap
COLLEGE PARK, Md.--(BUSINESS WIRE)--IonQ (NYSE: IONQ), a leading commercial quantum computing and networking company, today announced the successful completion of its acquisition of Lightsynq Technologies, Inc., a Boston-based startup specializing in photonic interconnects and quantum memory. This strategic acquisition accelerates IonQ's fault-tolerant quantum computing roadmap and advances progress toward the development of the quantum internet. Lightsynq's photonic interconnect platform supports high-fidelity, multi-nodal qubit operations and modularity, which are essential for scaling quantum computers. The company's innovations in quantum memory and repeater technology complement IonQ's trapped-ion quantum computing approach and will advance IonQ's quantum networking systems. 'With this acquisition, we're not just acquiring talent and technology, we're accelerating our development timeline to fault tolerant quantum computers and long distance networking capabilities,' said Niccolo de Masi, CEO of IonQ. 'This deal accelerates the shift from experimental bulk optics to scalable optical chips, moving us closer to commercializing our next generation of advanced quantum technologies and the quantum internet.' Founded by Harvard quantum networking experts and former AWS research leads Dr. Mihir Bhaskar, Dr. Bart Machielse, and Dr. David Levonian, Lightsynq has developed universal photonic interconnect solutions designed to link multiple quantum processing units (QPUs) with high bandwidth to scale quantum systems. 'IonQ is already a leader in enterprise-grade quantum computing and networking, and by joining forces, we're accelerating the path to modular architectures that will deliver data-center-scale quantum computers in the future,' said Dr. Mihir Bhaskar, CEO of Lightsynq. 'Our work will enable IonQ's systems to network at speed and scale, laying the foundation for distributed quantum computing.' As part of this acquisition, IonQ will add to its patent portfolio over 20 patents and patent applications related to quantum memory and interconnect technologies, further strengthening IonQ's intellectual property position in the quantum computing and networking industry. This acquisition augments IonQ's growing leadership in the quantum networking space, including its recent acquisitions of quantum networking companies Qubitekk and ID Quantique, and the development of a quantum computing and networking innovation center with EPB in Chattanooga, Tennessee. About IonQ IonQ, Inc. is a leading commercial quantum computing and networking company, delivering high-performance systems aimed at solving the world's largest and most complex commercial and research use cases. IonQ's current generation quantum computers, IonQ Forte and IonQ Forte Enterprise, are the latest in a line of cutting-edge systems, boasting 36 algorithmic qubits. The company's innovative technology and rapid growth were recognized in Newsweek's 2025 Excellence Index 1000, Forbes' 2025 Most Successful Mid-Cap Companies list, and Built In's 2025 100 Best Midsize Places to Work in Washington, D.C. and Seattle, respectively. Available through all major cloud providers, IonQ is making quantum computing more accessible and impactful than ever before. Learn more at About Lightsynq Lightsynq is a quantum interconnect company founded by Harvard quantum networking experts and former AWS research leads Dr. Mihir Bhaskar (CEO), Dr. Bart Machielse (CTO) and Dr. David Levonian (CPO). Lightsynq's founders built the first-ever quantum memory capable of extending the range of quantum networks, a key technology enabling quantum devices to connect together in a future Quantum Internet. Lightsynq's core mission is to use this same technology to build the world's best quantum interconnects to link quantum processors at high speeds and overcome the bottleneck of single-system scaling. IonQ Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words 'will,' 'growing,' 'accelerates,' 'accelerating,' 'advance,' 'advances,' and other similar expressions are intended to identify forward-looking statements. These statements include those related to IonQ's quantum computing and quantum networking capabilities and plans; IonQ's development towards the quantum internet; IonQ technology driving commercial quantum advantage in the future; IonQ delivering scalable, fault-tolerant quantum computing in the future; the relevance and utility of quantum algorithms and applications run on IonQ's quantum computers; the necessity, effectiveness, and future impacts of IonQ's offerings available today; and the scalability, fidelity, efficiency, viability, accessibility, effectiveness, importance, reliability, performance, speed, impact, practicality, feasibility, and commercial-readiness of IonQ's offerings. Forward-looking statements are predictions, projections, and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: IonQ's ability to implement its technical roadmap; changes in the competitive industries in which IonQ operates, including development of competing technologies; IonQ's ability to deliver, and customers' ability to generate, value from IonQ's offerings; IonQ's ability to deliver higher speed and fidelity gates with fewer errors, enhance information transfer and network accuracy, or reduce noise and errors; IonQ's ability to sell effectively to government entities and large enterprises; changes in laws and regulations affecting IonQ's and its suppliers' businesses; IonQ's ability to implement its business plans, forecasts, roadmaps and other expectations, to identify and realize partnerships and opportunities, and to engage new and existing customers; IonQ's ability to effectively enter new markets; IonQ's ability to deliver services and products within currently anticipated timelines; IonQ's inability to attract and retain key personnel; IonQ's inability to effectively integrate its acquisitions of Qubitekk, Inc. assets and close its acquisition of a majority interest in ID Quantique, SA; IonQ's customers deciding or declining to extend contracts into new phases; the inability of IonQ's suppliers to deliver components that meet expectations timely; changes in U.S. government spending or policy that may affect IonQ's customers; and risks associated with U.S. government sales, including availability of funding and provisions that allow the government to unilaterally terminate or modify contracts for convenience; changes in laws and regulations affecting IonQ's patents; and IonQ's ability to maintain or obtain patent protection for its products and technology, including with sufficient breadth to provide a competitive advantage. You should carefully consider the foregoing factors and the other risks and uncertainties disclosed in the Company's filings, including but not limited to those described in the 'Risk Factors' section of IonQ's most recent Quarterly Report on form 10-Q, Annual Report on form 10-K, and other documents filed by IonQ from time to time with the Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and IonQ assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. IonQ does not give any assurance that it will achieve its expectations. IonQ may or may not choose to practice or otherwise use the inventions described in the issued patents in the future.
Yahoo
an hour ago
- Yahoo
Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer
TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) ('Teva') announced today the pricing and early acceptance results of its previously announced tender offers (the 'Offers') to purchase for cash the outstanding notes issued by finance subsidiaries of Teva and guaranteed by Teva of the series described in the table below (the 'Notes') upon the terms of, and subject to the conditions as set out in, the Offer to Purchase, dated May 19, 2025 (the 'Offer to Purchase'). Capitalized terms used in this announcement but not otherwise defined shall have the meanings given to them in the Offer to Purchase. Upon the terms and subject to the conditions set forth in the Offer to Purchase, the early acceptance results and the Total Consideration for each applicable series of the Notes are set forth in the following table: Dollars or Euros per $1,000 or €1,000, as applicable, principal amount Capped Tender Offers Title of Notes Issuer CUSIP / ISIN / Common Code Principal Amount Tendered(2) Pool Tender Caps (purchase price)(1)(2) Acceptance Priority Level(3) Principal Amount to be Accepted Proration Factor Principal Amount Outstanding after Early Settlement Date Reference Security or Interpolated Mid-Swap Rate Fixed Spread (basis points)(7) Tender Offer Consideration (4) Early Tender Premium Total Consideration (4)(5) Pool 1 Tender Offers 3.150% Senior Notes due 2026 Teva Pharmaceutical Finance Netherlands III B.V. 88167AAE1 / US88167AAE10 (Registered) $2,602,331,000 $1,550,000,000 1 $1,579,185,000 60.74999% $1,798,459,000 N/A N/A $931.50 $50.00 $981.50 Pool 2 Tender Offers 4.750% Sustainability-Linked Senior Notes due 2027 Teva Pharmaceutical Finance Netherlands III B.V. 88167AAP6 / US88167AAP66 (Registered) $781,072,000 $350,000,000 (equivalent) 2 $350,877,000 39.4586% $649,123,000 N/A N/A $947.50 $50.00 $997.50 3.750% Sustainability-Linked Senior Notes due 2027 Teva Pharmaceutical Finance Netherlands II B.V. XS2406607098 / 240660709 (Registered) €532,083,000 3 €0 N/A €1,100,000,000 N/A N/A €963.50 €50.00 €1,013.50 Pool 3 Tender Offers 7.875% Sustainability-Linked Senior Notes due 2029 Teva Pharmaceutical Finance Netherlands III B.V. 88167AAS0 / US88167AAS06 (Registered) $202,316,000 $400,000,000(equivalent) 4 $202,316,000 N/A $397,684,000 4.016% + 135 $1,039.78 (6) $50.00 $1,089.78 (7) 7.375% Sustainability-Linked Senior Notes due 2029 Teva Pharmaceutical Finance Netherlands II B.V. XS2592804434 / 259280443 (Registered) €349,888,000 5 €137,418,000 36.663% €662,582,000 2.100% + 150 €1,091.64 (6) €50.00 €1,141.64 (7) 8.125% Sustainability-Linked Senior Notes due 2031 Teva Pharmaceutical Finance Netherlands III B.V. 88167AAR2 / US88167AAR23 (Registered) $116,975,000 6 $0 N/A $500,000,000 4.016% + 155 $1,079.49 (6) $50.00 $1,129.49 (7) (1) The tender cap for the Pool 1 Notes of $1,550,000,000 (the 'Pool 1 Tender Cap') represents the maximum aggregate purchase price in respect of Pool 1 Notes that will be purchased in the Pool 1 Tender Offers. The tender cap for the Pool 2 Notes of $350,000,000 (the 'Pool 2 Tender Cap') represents the maximum aggregate purchase price in respect of Pool 2 Notes that will be purchased in the Pool 2 Tender Offers. The tender cap for the Pool 3 Notes of $400,000,000 (the 'Pool 3 Tender Cap' and, together with the Pool 1 Tender Cap and the Pool 2 Tender Cap, the 'Pool Tender Caps') represents the maximum aggregate purchase price in respect of Pool 3 Notes that will be purchased in the Pool 3 Tender Offers. The Pool Tender Caps can be increased or decreased at Teva's sole discretion.(2) In order to determine whether the Total Maximum Amount and Pool Tender Caps have been reached, an exchange rate of $1.1443 = €1.00 has been used, as determined at 10:30 a.m. Eastern Time on the date of the Early Tender Time.(3) Subject to the Total Maximum Amount, the Pool Tender Caps and proration, the principal amount of each series of Notes that is purchased in each of the Offers will be determined in accordance with the applicable acceptance priority level (in numerical priority order) specified in this column.(4) Excludes accrued and unpaid interest, which also will be paid. The Total Consideration in respect of the Pool 3 Notes was calculated at 10:30 a.m., New York City time, on June 3, 2025 (the 'Price Determination Time') in accordance with standard market practice, as described in the Offer to Purchase.(5) Already includes the Early Tender Premium.(6) The Tender Offer Consideration in respect of the Notes of each relevant series equals the applicable Total Consideration minus the applicable Early Tender Premium.(7) The Total Consideration in respect of the Pool 3 Notes of each relevant series was calculated from the applicable Reference Yield and the applicable Fixed Spread and which, when calculated in such manner, already includes the applicable Early Tender Premium. The applicable Total Consideration was calculated with reference to the First Par Call Date, as detailed in the Offer to Purchase.(8) Pricing Source: BGN. Early participation results of the Offers were announced on June 3, 2025. The amounts of each series of Notes to be accepted are shown in the table. The Notes tendered with Acceptance Priority Level 4 shall be accepted in full without proration. The Notes with Acceptance Priority Levels 1, 2 and 5 shall be accepted subject to a proration factor of approximately 60.74999%, 39.4586% and 36.663%, respectively. In accordance with the applicable Acceptance Priority Levels, no Notes with Acceptance Priority Levels 3 and 6 will be accepted by Teva pursuant to the Offers. Subject to the terms and conditions of the Offers, Holders that validly tendered and did not validly withdraw their Notes at or prior to the Early Tender Time and whose Notes are accepted for purchase by Teva will be eligible to receive the applicable Total Consideration, which already includes the Early Tender Premium, together with an amount equal to the Accrued Interest. Teva expects the Initial Settlement Date to occur on June 5, 2025, the third business day after the Early Tender Time. The consummation of the Offers and Teva's obligation to accept and pay for the Notes validly tendered (and not validly withdrawn) pursuant to the Offers are subject to the satisfaction or waiver of certain conditions described in the Offer to Purchase and subject to the applicable Pool Tender Cap. Teva reserves the right, subject to applicable law, to amend or waive any and all conditions to the Offers. The Offers will expire at 5:00 p.m., Eastern Time, on Tuesday, June 17, 2025, unless extended or earlier terminated (as it may be extended or earlier terminated, the 'Expiration Time'). However, as Teva intends, subject to the terms and conditions of the Offers, to accept for purchase the Total Maximum Amount on the Initial Settlement Date, further tenders of Notes prior to the Expiration Time will not be accepted for purchase. The settlement of Teva's $2.3 billion (equivalent) senior notes offering on May 28, 2025 satisfied the financing condition to the Offer. The purchase price for the Dollar Notes and the Euro Notes will be paid in U.S. Dollars and Euros, respectively. BNP PARIBAS, HSBC Bank plc, Intesa Sanpaolo S.p.A., J.P. Morgan Securities plc and Merrill Lynch International (or their respective affiliates) are acting as the Dealer Managers for the Offers. The information and tender agent (the 'Information and Tender Agent') for the Offers is D.F. King. Copies of the Offer to Purchase are available by contacting the Information and Tender Agent at (800) 967-5068 (toll-free), (212) 269-5550 (collect) or +44 20-7920-9700 (UK) or by email at teva@ All documentation relating to the offer, together with any updates, will be available via the Offer Website: Questions regarding the Offers should be directed to BNP PARIBAS, at +33 1 55 77 78 94 (Europe), +1 (888) 210 4358 (U.S. Toll Free), +1 (212) 841 3059 (U.S.) or by email at to HSBC Bank plc, at +44 20 7992 6237 (Europe), +1 (888) HSBC-4LM (U.S. Toll Free), +1 (212) 525-5552 (Collect) or by email at LM_EMEA@ to Intesa Sanpaolo S.p.A., at +39 02 7261 6502 or by email at to J.P. Morgan Securities LLC at +1 (866) 834-4666 (U.S. toll free), +1 (212) 834-4818 (Collect), to J.P. Morgan Securities plc at +44 207 134 2468 (Europe) or by email at liability_management_emea@ and to Merrill Lynch International at +44 207 996 5420 (Europe), +1 (888) 292-0070 (U.S. Toll Free) or by email at This announcement shall not constitute an offer to sell, a solicitation to buy or an offer to purchase or sell any Notes. The Offers are being made only pursuant to the Offer to Purchase and only in such jurisdictions as is permitted under applicable law. About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a different kind of global biopharmaceutical leader, one that operates across the full spectrum of innovation to reliably deliver medicines to patients worldwide. For over 120 years, Teva's commitment to bettering health has never wavered. Today, the company's global network of capabilities enables its 37,000 employees across 57 markets to advance health by developing medicines for the future while championing the production of generics and biologics. We are dedicated to addressing patients' needs, now and in the future. Moving forward together with science that treats, inspired by the people we serve. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: settlement of the tender offers for certain outstanding notes; our significant indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments, and may result in a further downgrade of our credit ratings; our inability to raise debt or borrow funds in amounts or on terms that are favorable to us; and other factors discussed in our Quarterly Report on Form 10-Q for the first quarter of 2025, our Annual Report on Form 10-K for the year ended December 31, 2024, including the sections thereof captioned 'Risk Factors' and 'Forward Looking Statements,' and other filings with the SEC, which are available at Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements. No assurance can be given that the transactions described herein will be consummated or as to the ultimate terms of any such transactions. Teva Media Inquiries:TevaCommunicationsNorthAmerica@ Teva Investor Relations InquiresTevaIR@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
